BUSINESS
    Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
    October 27, 2021
    Sun Pharma Japan is set to augment its marketing organization and drug pipeline in a bid to solidify its business base. While the company’s operations currently revolve around dermatology, it is aiming its sights on…

    LATEST

    JGA Sets Out 5-Pronged Measures to Restore Trust in Generics
    October 27, 2021
    The Japan Generic Medicines Association (JGA) on October 25 announced a set of measures aimed at recovering trust in generic drugs, which were sorted under five themes including the strengthening of compliance and governance and…
    Nobelpharma Plans Launch of 3 Products in US, China, Europe: R&D Head
    October 27, 2021
    Nobelpharma is in discussions with regulatory authorities to launch three in-house products including Rapalimus Gel (sirolimus) in the US, Chinese, and European markets, R&D head Shigeki Shimasaki said at a media seminar on October 26.The three products being planned for…
    Solasia Grants Japan Rights for Darinaparsin to Nippon Kayaku, Ends Deal with Meiji
    October 27, 2021
    Solasia Pharma said on October 26 that it has terminated its license agreement with Meiji Seika Pharma for Japan rights to darinaparsin, a drug candidate for peripheral T-cell lymphoma (PTCL), while announcing a new pact with Nippon Kayaku.Solasia signed the…

    COMMENTARY

    SGLT2 Inhibitors, Entresto Could Change Paradigm of Treatment of Heart Failure: JHFS Annual Confab
    By Yasuchika Hisatani

    In early October, the Japanese Heart Failure Society (JHFS) held its first annual scientific meeting since it published a focused update of the heart failure treatment guidelines in March jointly with the Japanese Circulation Society. The confab featured a series…

    COLUMN

    What Is the Price of a Work-Life Balance?
    By Philip Carrigan

    If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…

    FY2021 Drug Maker Employment Survey

    Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players

    The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

    INTERVIEW

    From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
    By Yoshinori Sagehashi

    Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA